Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $26.16 USD
Change Today +0.29 / 1.12%
Volume 129.4K
OMED On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

oncomed pharmaceuticals inc (OMED) Snapshot

Open
$25.79
Previous Close
$25.87
Day High
$26.38
Day Low
$25.59
52 Week High
03/23/15 - $29.83
52 Week Low
08/14/14 - $16.57
Market Cap
785.1M
Average Volume 10 Days
153.0K
EPS TTM
$-1.68
Shares Outstanding
30.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCOMED PHARMACEUTICALS INC (OMED)

oncomed pharmaceuticals inc (OMED) Related Bloomberg News

View More Bloomberg News

oncomed pharmaceuticals inc (OMED) Related Businessweek News

No Related Businessweek News Found

oncomed pharmaceuticals inc (OMED) Details

OncoMed Pharmaceuticals, Inc., a clinical development-stage biotechnology company, discovers and develops protein therapeutics targeting cancer stem cells (CSCs). Its product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, as well as impact bulk tumor cells. The company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), a humanized monoclonal antibody that is in two Phase II clinical trials and one Phase Ib/II clinical trial for the treatment of patients with non-small-cell lung cancer and pancreatic cancer; Anti-DLL4/Anti-vascular endothelial growth factor (VEGF) Bispecific, which has completed preclinical trial that targets and inhibits DLL4 and vascular endothelial growth factor (VEGF); Tarextumab (Anti-Notch2/3, OMP-59R5), a human monoclonal antibody that targets the Notch2 and Notch3 receptors that is in Phase II clinical trials; Brontictuzumab (Anti-Notch1, OMP-52M51), a human monoclonal antibody, which completed single-agent Phase I trial for the treatment of solid tumor; and Vantictumab ((Anti-Fzd7, OMP-18R5) that completed a Phase I single-agent trial in tumor patients. Its products also include Ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based Frizzled8 receptor or Fzd8, which is in Phase I single agent trial; Wnt biologic #3, an additional bispecific biologic product candidate in preclinical studies; Wnt small molecule inhibitors, which is in preclinical testing; and RSPO-LGR, a CSC pathway that is in preclinical study of antibodies. OncoMed Pharmaceuticals, Inc. has strategic alliances with GlaxoSmithKline LLC to develop anti-CSC antibody therapeutics targeting the Notch signaling pathway; Bayer Pharma AG for anti-CSC biologic and small molecule therapeutics targeting the Wnt signaling pathway; and Celgene Corporation for anti-CSC product candidates. The company was founded in 2004 and is headquartered in Redwood City, California.

108 Employees
Last Reported Date: 03/12/15
Founded in 2004

oncomed pharmaceuticals inc (OMED) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $628.6K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $487.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $452.4K
Vice President and General Counsel
Total Annual Compensation: $383.8K
Compensation as of Fiscal Year 2013.

oncomed pharmaceuticals inc (OMED) Key Developments

OncoMed Pharmaceuticals, Inc. Initiates Dosing in Randomized Phase 2 Clinical Trial of Demcizumab in Pancreatic Cancer Patients

OncoMed Pharmaceuticals, Inc. announced that dosing has begun in the randomized Phase 2 clinical trial of demcizumab (anti-DLL4, OMP-21M18) in patients with first-line metastatic pancreatic cancer. The double-blind, placebo-controlled Phase 2 "YOSEMITE" clinical trial is designed to compare the efficacy and safety of demcizumab combined with standard of care Abraxane® (paclitaxel protein-bound particles for injectable suspension) (albumin bound) plus gemcitabine in patients with first-line metastatic pancreatic cancer. The primary endpoint of the trial is progression-free survival. Secondary endpoints include overall survival, response rate, duration of response, safety, immunogenicity and pharmacokinetics. Approximately 200 patients will be randomized into one of three study arms. Patients in Arm 1 will receive Abraxane plus gemcitabine (standard of care) plus placebo. Patients in Arm 2 will receive standard of care plus one course of demcizumab 3.5 mg/kg every two weeks for 70 days. Patients in Arm 3 will receive standard of care plus a second course of demcizumab following a 100-day wash out period. The Phase 2 trial is being conducted at approximately 50 centers in the U.S., Canada, Europe and Australia. OncoMed is eligible to achieve a $70 million milestone from Celgene for successful completion of an interim safety analysis associated with the two randomized demcizumab Phase 2 trials. The safety analysis will be performed by an independent data safety monitoring board (DSMB) using pre-specified safety criteria agreed to in the collaboration agreement and is expected to occur in late 2015/early 2016.

OncoMed Pharmaceuticals, Inc. Presents Demcizumab Data from Phase 1b Clinical Trial in Non-Small Cell Lung Cancer Patients at the European Lung Cancer Conference

OncoMed Pharmaceuticals Inc. presented new data from the Phase 1b clinical trial of demcizumab (anti-DLL4, OMP-21M18) in patients with first-line advanced non-small cell lung cancer (NSCLC) at the European Lung Cancer Conference. Demcizumab is a first-in-class monoclonal antibody targeting DLL4 with anti-cancer stem cell, dysangiogenesis and potential immune modulatory properties. The Phase 1b trial studied several doses of demcizumab (2.5, 5, and 7.5 mg/kg) in combination with carboplatin and pemetrexed every three weeks. Twenty-three subjects received continuous dosing of demcizumab with up to six cycles of pemetrexed and carboplatin followed by demcizumab maintenance. Twenty-three subjects received a truncated dosing schedule of demcizumab for four doses with pemetrexed and carboplatin, followed by pemetrexed maintenance. Of 40 patients evaluable for efficacy, the overall RECIST response rate was 50% and an additional 15 patients had a best response of stable disease, yielding a clinical benefit rate of 88%. Median progression-free survival (PFS) based on Kaplan-Meier estimates was 5.3 months and 5.8 months for the continuous and truncated cohorts, respectively. A worst-case analysis (to ensure that Kaplan-Meier estimates are not impacted by selective reporting) showed a median overall survival (OS) of 6.3 months for the continuous demcizumab cohort, and a median OS of 8.1 months for the truncated dose patients. Prolonged PFS and OS were observed for a subset of patients treated with continuous demcizumab. This was apparent by the plateau at the tail end of the Kaplan Meier curve. Specifically, of the 23 patients in the continuous dosing group, ten survived more than 300 days. In these 10 patients who survived more than 300 days, there was a cumulative 21.8 years of patient follow-up beyond those 300 days, and among these ten patients, only two patient deaths occurred as of the February 26, 2015 data cut off. Survival data from patients treated with the truncated demcizumab dose regimen is less mature, although the Kaplan-Meier curves, as of the February cut-off date, show a similar trajectory. A randomized Phase 2 trial (DENALI) of demcizumab with carboplatin and pemetrexed in first-line non-squamous NSCLC has been initiated and is enrolling subjects in Europe, Australia, and the United States. The regimen of demcizumab, pemetrexed and carboplatin was generally well-tolerated with fatigue, nausea and manageable hypertension being the most common demcizumab-related toxicities. Two cases of reversible Grade 3 pulmonary hypertension and heart failure occurred earlier in the trial in patients treated with continuous demcizumab for greater than 160 days. Subsequent patients were treated with a truncated risk mitigating demcizumab regimen (i.e., 63 days of treatment). The truncated demcizumab treatment and patient monitoring with BNP and ECHO appears to prevent the onset of late cardiopulmonary toxicity. There were no incidents of moderate-to-severe cardiopulmonary toxicity events observed using the truncated dosing regimen. The Phase 2 dose of demcizumab at 5mg/kg every three weeks administered on a truncated dosing schedule was selected. Pharmacodynamic analyses of gene expression of patient samples demonstrated clear modulation of the Notch pathway that lasted up to 77 days after the last dose of study drug.

OncoMed Pharmaceuticals, Inc. and Eli Lilly Enter Clinical Supply Agreement to Evaluate the Combination of Demcizumab and Alimta(R) in Lung Cancer

OncoMed Pharmaceuticals, Inc. announced that it has entered into an agreement with Eli Lilly and Company. Demcizumab, OncoMed's anti-DLL4 antibody, is being tested in combination with Lilly's Alimta® (pemetrexed for injection) and carboplatin for the treatment of first-line advanced non-small cell lung cancer (NSCLC). Under the terms of this agreement, Lilly will provide clinical supply of Alimta for OncoMed's ongoing Phase 2 DENALI trial. OncoMed initiated enrollment in the randomized Phase 2 DENALI trial in January 2015 to test the efficacy and safety of demcizumab in combination with Alimta and carboplatin. Alimta is approved as an initial treatment in combination with cisplatin for locally advanced or metastatic NSCLC for patients with non-squamous histology. The DENALI trial is expected to enroll approximately 200 patients with first-line metastatic Stage IV non-squamous NSCLC whose tumors do not have an epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutation.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OMED:US $26.16 USD +0.29

OMED Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OMED.
View Industry Companies
 

Industry Analysis

OMED

Industry Average

Valuation OMED Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.7x
Price/Book 10.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOMED PHARMACEUTICALS INC, please visit www.oncomed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.